Axsome Therapeutics (AXSM) Gains from Sales and Divestitures (2022 - 2025)
Historic Gains from Sales and Divestitures for Axsome Therapeutics (AXSM) over the last 4 years, with Q3 2025 value amounting to $295835.0.
- Axsome Therapeutics' Gains from Sales and Divestitures rose 1948.34% to $295835.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $295835.0, marking a year-over-year increase of 1948.34%. This contributed to the annual value of $267779.0 for FY2024, which is 3772.87% up from last year.
- Per Axsome Therapeutics' latest filing, its Gains from Sales and Divestitures stood at $295835.0 for Q3 2025, which was up 1948.34% from $268394.0 recorded in Q2 2025.
- In the past 5 years, Axsome Therapeutics' Gains from Sales and Divestitures ranged from a high of $295835.0 in Q3 2025 and a low of $61581.0 during Q1 2022
- Moreover, its 4-year median value for Gains from Sales and Divestitures was $194425.0 (2023), whereas its average is $181884.0.
- As far as peak fluctuations go, Axsome Therapeutics' Gains from Sales and Divestitures soared by 16114.95% in 2023, and later skyrocketed by 1606.2% in 2025.
- Over the past 4 years, Axsome Therapeutics' Gains from Sales and Divestitures (Quarter) stood at $81639.0 in 2022, then soared by 138.15% to $194425.0 in 2023, then surged by 37.73% to $267779.0 in 2024, then rose by 10.48% to $295835.0 in 2025.
- Its last three reported values are $295835.0 in Q3 2025, $268394.0 for Q2 2025, and $244299.0 during Q1 2025.